• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Elanco Animal Health Incorporated (Amendment)

    2/13/24 2:08:55 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ELAN alert in real time by email
    SC 13G/A 1 d759338dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 13G

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    (AMENDMENT NO. 3 )*

     

     

    Elanco Animal Health Incorporated

    (Name of Issuer)

    Common Stock

    (Title of Class of Securities)

    28414H103

    (CUSIP Number)

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

    PAGE 1 OF 5 PAGES


    CUSIP NO. 28414H103    13G    PAGE 2 OF 5 PAGES

     

     1   

     NAME OF REPORTING PERSON

     S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

     

     Dodge & Cox    94-1441976

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

     (a) ☐  (b) ☐

     

     N/A

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     California - U.S.A.

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     79,276,700

       6  

     SHARED VOTING POWER

     

     0

       7  

     SOLE DISPOSITIVE POWER

     

     83,980,900

       8  

     SHARED DISPOSITIVE POWER

     

     0

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     83,980,900

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     

     N/A

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     17.0%

    12  

     TYPE OF REPORTING PERSON*

     

     IA

    PAGE 2 OF 5 PAGES


    Item 1(a) 

    Name of Issuer:

    Elanco Animal Health Incorporated

     

    Item 1(b) 

    Address of Issuer’s Principal Executive Offices:

    2500 Innovation Way

    Greenfield, Indiana 46140

     

    Item 2(a) 

    Name of Person Filing:

    Dodge & Cox

     

    Item 2(b) 

    Address of the Principal Office or, if none, Residence:

    555 California Street, 40th Floor

    San Francisco, CA 94104

     

    Item 2(c) 

    Citizenship:

    California - U.S.A.

     

    Item 2(d) 

    Title of Class of Securities:

    Common Stock

     

    Item 2(e) 

    CUSIP Number:

    28414H103

     

    Item 3 

    If the Statement is being filed pursuant to Rule 13d-1(b), or 13d-2(b), check whether the person filing is a:

     

      (e)

    ☒ Investment Advisor registered under section 203 of the Investment Advisors Act of 1940

     

    Item 4 

    Ownership:

     

      (a)

    Amount Beneficially Owned:

    83,980,900

     

      (b)

    Percent of Class:

    17.0%

     

    PAGE 3 OF 5 PAGES


      (c)

    Number of shares as to which such person has:

     

      (i)

    sole power to vote or direct the vote:

    79,276,700

     

      (ii)

    shared power to vote or direct the vote:

    0

     

      (iii)

    sole power to dispose or to direct the disposition of:

    83,980,900

     

      (iv)

    shared power to dispose or to direct the disposition of:

    0

     

    Item 5 

    Ownership of Five Percent or Less of a Class:

    Not applicable.

     

    Item 6 

    Ownership of More than Five Percent on Behalf of Another Person:

    The clients of Dodge & Cox, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or power to direct the receipt of dividends from, and the proceeds from the sale of, Elanco Animal Health Incorporated.

    Dodge & Cox Stock Fund, an investment company registered under the Investment Company Act of 1940, has an interest of 55,396,500 or 11.2%, of the class of securities reported herein.

     

    Item 7 

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company:

    Not applicable.

     

    Item 8 

    Identification and Classification of Members of the Group:

    Not applicable.

     

    Item 9 

    Notice of Dissolution of a Group:

    Not applicable.

     

    Item 10 

    Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired for the purpose of and do not have the effect of changing or influencing the control of the issuer of such securities and were not acquired in connection with or as a participant in any transaction having such purpose or effect.

     

    PAGE 4 OF 5 PAGES


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: February 13, 2024

     

    DODGE & COX

    By:

     

    /S/ Katherine M. Primas

    Name:  

    Katherine M. Primas

    Title:

     

    Chief Compliance Officer

     

    PAGE 5 OF 5 PAGES

    Get the next $ELAN alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ELAN

    DatePrice TargetRatingAnalyst
    6/26/2025Mkt Perform → Outperform
    William Blair
    12/9/2024$18.00Buy
    UBS
    12/2/2024$14.00Market Perform
    Leerink Partners
    9/19/2024$17.00 → $15.00Overweight → Equal-Weight
    Morgan Stanley
    1/5/2024$13.00 → $20.00Hold → Buy
    Stifel
    12/19/2023$17.00Buy
    Jefferies
    12/15/2023$16.00Equal-Weight → Overweight
    Morgan Stanley
    12/7/2023$18.00Outperform
    Exane BNP Paribas
    More analyst ratings

    $ELAN
    SEC Filings

    See more
    • Elanco Animal Health Incorporated filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

      8-K - Elanco Animal Health Inc (0001739104) (Filer)

      6/26/25 4:01:32 PM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SD filed by Elanco Animal Health Incorporated

      SD - Elanco Animal Health Inc (0001739104) (Filer)

      5/30/25 10:00:37 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Elanco Animal Health Incorporated filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Elanco Animal Health Inc (0001739104) (Filer)

      5/28/25 7:30:32 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ELAN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Elanco Confirms Date and Conference Call for Second Quarter 2025 Financial Results Announcement

      GREENFIELD, Ind., July 10, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) will announce its second quarter 2025 financial results on Thursday, August 7, 2025. Elanco will also conduct a conference call on that day with the investment community and media to provide further details about the company's performance. The conference call will begin at 8:00 a.m. Eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link posted on Elanco's website at https://investor.elanco.com/events-and-presentations/d

      7/10/25 8:00:00 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Elanco Receives USDA Approval for TruCan™ Ultra CIV H3N2/H3N8 (Canine Influenza Vaccine) Bringing to Market a High Standard of Respiratory Protection

      TruCan Ultra CIV is the only ½ mL bivalent Canine Influenza Virus (CIV) vaccine offering broad protection against H3N2 and H3N8.100% virus neutralization against 33 current field isolates.1Unlike currently available products, only TruCan Ultra CIV demonstrates zero lung lesions in vaccinated dogs post H3N2 challenge.2,3,4TruCan Ultra CIV completes Elanco's extensive line of Tru Portfolio vaccines.GREENFIELD, Ind., July 9, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today announced the U.S. Department of Agriculture (USDA) has approved TruCan Ultra CIV H3N2/H3N8, a canine influenza vaccine designed to provide broad respiratory disease protection. The approval of TruCan

      7/9/25 8:27:00 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Neurizon Enters into Global License with Elanco to Accelerate Commercialisation of NUZ-001

      Highlights: Neurizon® Therapeutics and Elanco Animal Health enter into an exclusive global licensing agreement Provides worldwide rights for Neurizon to utilise Elanco's intellectual property, providing exclusive access to an extensive package of non-clinical studies and manufacturing data and outlines key terms for a future supply agreement for GMP-compliant MonepantelProvides a clear pathway for accelerated global commercialisation of NUZ-001[1] and significantly de-risks future global regulatory approval processesThe license agreement represents the first step in formalising Neurizon's relationship with Elanco, with the next step focused on finalising a supply agreement expected H2 CY 202

      7/2/25 7:09:00 PM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ELAN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Elanco Animal Health upgraded by William Blair

      William Blair upgraded Elanco Animal Health from Mkt Perform to Outperform

      6/26/25 7:49:03 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UBS initiated coverage on Elanco Animal Health with a new price target

      UBS initiated coverage of Elanco Animal Health with a rating of Buy and set a new price target of $18.00

      12/9/24 7:40:18 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Leerink Partners initiated coverage on Elanco Animal Health with a new price target

      Leerink Partners initiated coverage of Elanco Animal Health with a rating of Market Perform and set a new price target of $14.00

      12/2/24 6:55:44 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ELAN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHIEF ACCOUNTING OFFICER Meer James M covered exercise/tax liability with 1,161 shares, decreasing direct ownership by 2% to 58,103 units (SEC Form 4)

      4 - Elanco Animal Health Inc (0001739104) (Issuer)

      7/8/25 4:19:02 PM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP, MANUFACTURING AND QUALITY Mcardle Grace covered exercise/tax liability with 4,346 shares, decreasing direct ownership by 5% to 76,049 units (SEC Form 4)

      4 - Elanco Animal Health Inc (0001739104) (Issuer)

      7/8/25 4:17:14 PM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Anand Kapila K

      4 - Elanco Animal Health Inc (0001739104) (Issuer)

      7/2/25 4:16:24 PM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ELAN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Kurzius Lawrence Erik bought $211,000 worth of shares (20,000 units at $10.55), increasing direct ownership by 22% to 111,459 units (SEC Form 4)

      4 - Elanco Animal Health Inc (0001739104) (Issuer)

      3/11/25 5:13:30 PM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Hoover R David bought $272,558 worth of shares (25,000 units at $10.90) (SEC Form 4)

      4 - Elanco Animal Health Inc (0001739104) (Issuer)

      3/7/25 4:21:21 PM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Harrington Michael J bought $51,974 worth of shares (3,500 units at $14.85), increasing direct ownership by 5% to 81,094 units (SEC Form 4)

      4 - Elanco Animal Health Inc (0001739104) (Issuer)

      8/26/24 5:05:35 PM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ELAN
    Leadership Updates

    Live Leadership Updates

    See more
    • Elanco Releases New Report Highlighting the Significance of America's Itchy Dogs and the Need for Itch Relief

      The first-of-its-kind report includes results from multiple surveys revealing just how badly dogs around the country are itching for relief.Data reveals that nearly 9 in 10 dogs in the U.S. are "itchy dogs" according to their pet owners, having experienced symptoms of itchiness at some point in the year.1Allergy season makes itch worse, with 83% of pet owners saying that increased pollen levels affect their dog's itch.1Veterinarians are the most trusted ally in solving dogs' itch, and the majority of veterinarians say that itchiness is the most frustrating issue they deal with.1Leading veterinarians and canine dermatologists, including Drs. Joya Griffin, Andrew Rosenberg, and Tom Lewis, are

      6/5/25 7:45:00 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Elanco Appoints Robert (Bob) VanHimbergen as Chief Financial Officer

      GREENFIELD, Ind., May 28, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today announced the appointment of Robert VanHimbergen as Executive Vice President and Chief Financial Officer, effective July 7, 2025. VanHimbergen's appointment follows an extensive and competitive search as part of the company's commitment to long-term, sustained value creation. VanHimbergen succeeds Todd Young, who will remain with the company as an advisor through August 31, 2025, to facilitate a smooth transition. VanHimbergen currently serves as the Senior Vice President and Chi

      5/28/25 7:25:00 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Elanco Strengthens Board of Directors with Addition of Stacey Ma

      Ma brings deep manufacturing and innovation expertise GREENFIELD, Ind., Nov. 12, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today announced the appointment of Dr. Stacey Ma to its Board of Directors, effective immediately. Dr. Ma brings extensive global leadership experience in biopharmaceutical development and manufacturing, further strengthening Elanco's expertise in these critical areas. "We are delighted to add Stacey to the Elanco Board," said Lawrence Kurzius, Chairman of the Elanco Board of Directors. "Her deep understanding of product developmen

      11/12/24 8:33:00 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ELAN
    Financials

    Live finance-specific insights

    See more
    • Elanco Confirms Date and Conference Call for Second Quarter 2025 Financial Results Announcement

      GREENFIELD, Ind., July 10, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) will announce its second quarter 2025 financial results on Thursday, August 7, 2025. Elanco will also conduct a conference call on that day with the investment community and media to provide further details about the company's performance. The conference call will begin at 8:00 a.m. Eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link posted on Elanco's website at https://investor.elanco.com/events-and-presentations/d

      7/10/25 8:00:00 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Elanco Animal Health Reports First Quarter 2025 Results

      Accelerating Debt Paydown in 2025 First Quarter 2025 Financial Results:Revenue of $1,193 million, a decline of 1% year-over-year; 4% organic constant currency growthReported Net Income of $67 million, Adjusted Net Income of $184 millionAdjusted EBITDA of $276 million, or 23.1% of RevenueReported EPS of $0.13, Adjusted EPS of $0.37Net leverage ratio of 4.4x Adjusted EBITDAFull Year 2025 Guidance:Raising revenue guidance to $4,510 to $4,580 million, with $65 to $70 million increase since February driven by foreign exchange tailwind; continue to expect accelerating organic constant currency revenue growth to mid-single digitsRaising 2025 innovation revenue target to $660 to $740 millionReported

      5/7/25 6:27:00 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Elanco Confirms Date and Conference Call for First Quarter 2025 Financial Results Announcement

      GREENFIELD, Ind., April 10, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) will announce its first quarter 2025 financial results on Wednesday, May 7, 2025. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance. The conference call will begin at 8:00 a.m. eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link that will be posted on Elanco's website at https://investor.elanco.com/events-and-presentations/defau

      4/10/25 8:00:00 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ELAN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Elanco Animal Health Incorporated

      SC 13G/A - Elanco Animal Health Inc (0001739104) (Subject)

      7/8/24 4:32:39 PM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Elanco Animal Health Incorporated (Amendment)

      SC 13G/A - Elanco Animal Health Inc (0001739104) (Subject)

      2/13/24 2:08:55 PM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Elanco Animal Health Incorporated (Amendment)

      SC 13G/A - Elanco Animal Health Inc (0001739104) (Subject)

      2/12/24 4:01:30 PM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care